MedTrace Logo

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

NCT05364021 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-11-08

No results posted yet for this study

Summary

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Conditions

  • Developmental and Epileptic Encephalopathy
  • Dravet Syndrome
  • Lennox Gastaut Syndrome

Interventions

DRUG

LP352

LP352 administered three times daily, orally or through G-tube

DRUG

Placebo

Matching placebo for LP352 administered three times daily, orally or through G-tube

Sponsors & Collaborators

  • Longboard Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dennis J Dlugos, MD · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2023-11-16
Completion
2023-11-20
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364021 on ClinicalTrials.gov